Navigation Links
ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
Date:1/25/2008

TUCSON, Ariz., Jan. 25 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. (Nasdaq: IMRX) today announced that the Food and Drug Administration (FDA) has approved the company's most current lot release request for urokinase drug product. This is the first lot to be released with extended expiration dating. Urokinase, ImaRx's first commercially available FDA-approved product, is a thrombolytic or clot-dissolving agent indicated for the treatment of acute massive pulmonary embolism.

"The FDA approval of urokinase lot release brings several advantages to ImaRx," said Bradford A. Zakes, President and CEO of ImaRx. "The extended expiration dating allows us to unlock the value from our unlabeled urokinase inventory. We will also benefit from cost-savings associated with prolonged shelf-life for future urokinase supplies."

ImaRx is continuing its stability program to evaluate the potential for further expiration extensions beyond September 2009 for unlabeled vials of urokinase inventory.

In January 2008, ImaRx and Microbix Biosystems Inc. signed a letter of intent to manufacture urokinase and explore development of additional indications. Microbix is believed to be the only supplier capable of producing urokinase on a commercial scale at its production facility in Toronto. As part of the agreement, ImaRx will retain existing urokinase inventory and intends to transfer the manufacturing process and NDA to Microbix. With Microbix as its long-term supplier, ImaRx will continue to market urokinase for acute massive pulmonary embolism, while Microbix will have development rights for certain new indications.

About ImaRx Therapeutics

ImaRx Therapeutics is a biopharmaceutical company commercializing and developing thera
'/>"/>

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
2. Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management
3. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
4. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
5. Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
6. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
7. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
8. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
9. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
10. Sirnaomics Received Multiple Government Fundings For Its Multi-Targeted siRNA Therapeutics Programs
11. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., , BEIJING, Nov. 25 /PRNewswir...developer and provider of vaccines, announced toda...to establish Sinovac (Dalian) Vaccine,Technology C...evelop, produce,and commercialize human-use vaccin...rience in developing and commercializing world-cla...
(Date:11/25/2009)..., , SAN DIEGO, Nov. 25 /PRNewswire-FirstC...nnounced today that Barry D. Quart, Pharm.D., pres... the Piper Jaffray 21st Annual Health Care Confere...er Jaffray 21st Annual Health Care Conference,Date....m. Eastern Time,Location: The New York Palace Ho...
(Date:11/24/2009)..., , HOUSTON, Nov. 24 /PRNewswire-First...provider of electrical and communications systems ...sidential markets, announced today that its commer...om Manhattan Torcon JV to install the electrical s...acement facility at the U.S. Army Medical Research...
(Date:11/24/2009)... The New York investment ...td (ASX:NEU) has agreed an AU$6.7 mil convertible ...nvestor. The private placement was arranged by KTA... advisor. , New York (PRW...investment bank KTA Capital, LLC ("KTA Capita...
Breaking Biology Technology:Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2
...provider of centralized ECG and eClinical technolo...cal, medical device, and related industries, annou...o of products and services on Booth #1253/1254 at ...in Berlin, Germany. ERT is also inviting attendees...e impact of technology and standards on drug deliv...
...orate partially absorbable mesh for use in the tre...d to improve healing and patient comfort , , SO...amp; Urology, a division of Ethicon, Inc., a Johns... GYNECARE PROLIFT+M(TM) Pelvic Floor Repair System...surgery to treat pelvic organ prolapse. GYNECARE P...
...arma Ltd., a,privately-held drug development compa...ed that it has begun a new Phase IIa clinical test... novel topical drug for,dermatology. The double-bl...ate the tolerability, pharmacokinetics, and effica...s with mild to moderate plaque psoriasis. The,subj...
Other Biology Technology:ERT to Showcase Its Clinical Trials Portfolio at DIA's 21st Euromeeting 2ERT to Showcase Its Clinical Trials Portfolio at DIA's 21st Euromeeting 3GYNECARE PROLIFT+M(TM) Pelvic Floor Repair System Launched in US for Use in Pelvic Organ Prolapse Surgery 2GYNECARE PROLIFT+M(TM) Pelvic Floor Repair System Launched in US for Use in Pelvic Organ Prolapse Surgery 3BioCis Pharma Starts Phase IIa Trial in Psoriasis 2
(Date:11/30/2009)... University researchers Ron Falta and Larry Murdoc...on Agency grant to study the safe storage of carbo...low the earth,s surface. , With carbon dioxide e...the leading cause of global warming, geologic stor...atives for reducing emissions using current techno...
(Date:11/30/2009)...esearchers from LSU Health Sciences Center New Orl...er National Institute of Child Health and Human De..., Brigham and Women,s Hospital, and Harvard Medica...ing more than 5 servings of sugar- sweetened cola ... elevate the risk of developing diabetes during pr...
(Date:11/30/2009)...sion proteins are crucial for infection. Each bind...s, which stimulates the host cell to take up the p...a different function, for example the regulation o...ts have now been published in the current issue of... meat is one of the sources for Listeria infecti...
Breaking Biology News(10 mins):Sugary cola drinks linked for first time to higher risk of gestational diabetes 2Sugary cola drinks linked for first time to higher risk of gestational diabetes 3It takes 2 to infect 2UAB research finds childbearing increases chance of developing the metabolic syndrome 10040 1UAB research finds childbearing increases chance of developing the metabolic syndrome 10040 2From Kindergarten to College Go Back to School in Better Health 58069 1From Kindergarten to College Go Back to School in Better Health 58069 2From Kindergarten to College Go Back to School in Better Health 58069 3From Kindergarten to College Go Back to School in Better Health 58069 4Data Show Long Term Mechanical Integrity of MitraClip 28R 29 and Complete Healing Following Implantation of the Device for Mitral Valve Repair 58066 1Data Show Long Term Mechanical Integrity of MitraClip 28R 29 and Complete Healing Following Implantation of the Device for Mitral Valve Repair 58066 2Data Show Long Term Mechanical Integrity of MitraClip 28R 29 and Complete Healing Following Implantation of the Device for Mitral Valve Repair 58066 3
...he academic journal Mammal Review has uncovered th...vaquita. With a body less than 1.5 m long, the vaq...tacea consists of whales, dolphins and porpoises)....m2) and one of the smallest populations ( , The va...e Gulf of California (north of 30ยบ45,N and mainly ...
...s Hopkins, High Throughput Biology Center have inv... used to help identify otherwise elusive disease-c...ong believed to be "junk." , A variety of DNA micr...d the TIP-chip (transposable element insertion poi...ng genes have landed and disrupted normal gene fun...
...rected by Scripps Research Professor Benjamin Crav...issue of The Journal of Biological Chemistry. , Th... one previously suggested-for the biosynthesis of ...s), which include the endogenous cannabinoid ("end...e enzyme a/b hydrolase4 (Abh4) in areas such as th...
Other Biology News:Small, smaller, smallest -- The plight of the vaquita 2Small, smaller, smallest -- The plight of the vaquita 3Small, smaller, smallest -- The plight of the vaquita 4Taking 'chips' to the next level of gene hunting 2Taking 'chips' to the next level of gene hunting 3'Conversation stoppers' fight deadly bacterial infections 2
Bovine Albumin from Bovine Serum, Tetramethylrhodamine conjugated/tagged from Molecular Probes (Invitrogen)
...t Services are uniquely positioned to help you pre...rogens experts employ sophisticated, proprietary t...teins that match your needs: Structure/Function St... (metabolic labelling), Protein-protein interactio...
Bovine Albumin from Bovine Serum, Fluorescein conjugated/tagged from Molecular Probes (Invitrogen)
Mouse Anti-L1 Protein of Human Papilloma Virus Monoclonal Antibody, Unconjugated, Clone CAMVIR-1 from BD Biosciences Pharmingen
Biology Products: